Form 4: Axogen Director Alan Levine Receives Annual Equity Grant of 14,150 Restricted Stock Units

Axogen, Inc. Director Alan M Levine was granted 14,150 restricted stock units as part of his annual equity compensation, valued at $150,000, vesting on June 19, 2026.

Summary

• Alan M Levine, a Director of Axogen, Inc. (AXGN), received an annual equity grant of 14,150 Restricted Stock Units (RSUs).
• The grant was made on June 19, 2025, as part of his compensation for service on the Axogen, Inc. Board of Directors.
• Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
• The total valuation of this equity grant was $150,000 as of the grant date.
• These RSUs are scheduled to vest on June 19, 2026, which marks the one-year anniversary of the grant date.
• Following this reported transaction, Alan M Levine beneficially owns 14,150 Restricted Stock Units.

Sentiment

Score: 7

Explanation: The document reports a standard, expected event (director equity compensation) which is generally positive for corporate governance and alignment of interests, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of Restricted Stock Units aligns the director's interests with long-term shareholder value, as the units vest over time.
• This is a standard form of compensation for board members, indicating continuity in corporate governance practices and a commitment to retaining experienced leadership.

Negatives

• No specific negative aspects are detailed in this Form 4 filing, as it primarily reports a routine compensation event.

Risks

• No specific risks are mentioned in this Form 4 filing, as it is a disclosure of an insider transaction rather than a comprehensive risk assessment.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance beyond the vesting schedule of the granted units, as its purpose is to report a specific insider transaction.

Industry Context

This filing represents a routine compensation event for a director of a publicly traded company in the healthcare/medical device sector (Axogen, Inc. specializes in peripheral nerve repair). Such equity grants are common practice across industries to incentivize long-term commitment and align director interests with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a common practice across publicly traded companies, including those in the medical technology and biotechnology sectors.
• The valuation of $150,000 for an annual equity grant to a director is within the typical range observed for non-executive directors at companies of similar market capitalization and industry, though specific comparisons would require detailed compensation reports from peers like Integra LifeSciences Holdings Corporation (IART), Nevro Corp. (NVRO), or Stryker Corporation (SYK) to assess precise alignment.
• The one-year vesting period is also a standard approach for annual director equity awards, promoting retention and aligning interests over the short to medium term.

Corporate Governance

Related Party Transactions

• The equity grant of 14,150 Restricted Stock Units to Alan M Levine, a Director of Axogen, Inc., constitutes a related party transaction, which is a standard and disclosed form of executive and director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value, as the value of the compensation is tied to the company's stock performance.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The 14,150 Restricted Stock Units are scheduled to vest on June 19, 2026, at which point they will convert into shares of Axogen, Inc. common stock.

Key Dates

Recommendation

Keywords

Axogen, AXGN, SEC Form 4, Restricted Stock Units, RSU, Equity Grant, Director Compensation, Insider Transaction, Beneficial Ownership, Corporate Governance